N/A N=20 Imaging Airway Liquid Absorption in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 34.0; 17.7 percent cleared / 80 minutes — p=0.002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=28 FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Estrogen Receptor Positive · HER2/Neu Negative · Male Breast Carcinoma
Primary: Percent Change in Net Influx Constant (Ki) by FLT PET — -32.0 % change — p=0.51
Phase 3 N=76 Telotristat Etiprate for Carcinoid Syndrome Therapy
Carcinoid Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period — 21; 25; 22 Participants
Phase 2 N=91 Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)
Huntington's Disease
Primary: Tolerability as Assessed by Ability to Complete the Study on the Originally Randomized Treatment Assignment. — 90.0; 93.1; 81.3 percentage of participants
N/A N=130 Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
Acute Coronary Syndrome (ACS)
Primary: Adherence to Refills and Medications Scale (ARMS) — 12.03; 12.18 units on a scale
N/A N=210 A Representational Intervention to Promote Preparation for End-of-life Decision Making
End Stage Renal Disease
Primary: Dyad Congruence — 48; 64 percentage of congruent dyads — p=<.05
N/A N=221 Effect of Spinal Manipulation on Sensorimotor Functions in Back Pain Patients
Low Back Pain
Primary: Postural Sway — -.13; -0.26; -0.18; -0.06 mm
N/A N=24 New Generation Enlite Accuracy Study
Diabetes
Primary: Sensor Accuracy — 9.13 percentage
Phase 2 N=58 AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
Multiple System Atrophy, MSA
Primary: Striatum Brain Region: Change From Baseline in Microglia Activation Via Positron Emission Tomography(PET) — -0.23; 0.12; -0.35 ml/cc — p=0.13
N/A N=117 Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Improvement in ADHD Severity From Baseline to End of Intervention — 3.0; 3.2 units on a scale
Phase 4 N=17 Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients
Arteriovenous Fistula
Primary: Clotting TIme — 6; 8 minutes
Phase 3 N=616 A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 562 Participants
Phase 3 N=2,032 Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System
Healthy
Primary: Contraception Efficacy of AG200-15 in Subjects ≤ 35 Years of Age Regardless of BMI, Intent-to-treat (ITT) Dataset. — 5.80 Pearl Index
N/A N=60 A Study to Help People Quit Smoking.
Nicotine Dependence
Primary: Smoking Choice Procedure — 3.00; 1.00; 0.85 # of choices to smoke (out of 10)
Phase 4 N=71 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS
Ovarian Hyperstimulation Syndrome
Primary: Ongoing Pregnancy — 15; 19 participants